Filings

6 documents · 38 matches

1. PTIX Protagenic Therapeutics, Inc.new 10-K 2026-08-14

   Item 9A. Controls and Procedures.

   material weaknesses still exist and that such controls are not effective under the COSO framework. These material weaknesses could result
   5 matches in this document Show context Copy citation

2. PTIX Protagenic Therapeutics, Inc.new 10-Q 2026-11-06

   Item 4. Controls and Procedures

   material weaknesses in our internal control over financial reporting. Due to material weaknesses, our principal executive officer and principal financial
   6 matches in this document Show context Copy citation

3. PTIX Protagenic Therapeutics, Inc.new 10-Q 2026-08-19

   Item 4. Controls and Procedures

   material weaknesses in our internal control over financial reporting. Due to material weaknesses, our principal executive officer and principal financial
   6 matches in this document Show context Copy citation

4. PTIX Protagenic Therapeutics, Inc.new 10-Q 2026-03-09

   Item 4. Controls and Procedures

   material weaknesses in our internal control over financial reporting. Due to material weaknesses, our principal executive officer and principal financial
   7 matches in this document Show context Copy citation

5. PTIX Protagenic Therapeutics, Inc.new 10-Q 2025-11-26

   Item 4. Controls and Procedures

   material weaknesses in our internal control over financial reporting. Due to material weaknesses, our principal executive officer and principal financial
   7 matches in this document Show context Copy citation

6. PTIX Protagenic Therapeutics, Inc.new 10-Q 2025-05-13

   Item 4. Controls and Procedures

   material weaknesses in our internal control over financial reporting. Due to material weaknesses, our principal executive officer and principal financial
   7 matches in this document Show context Copy citation